Cancer Biomarkers Market value predicted to surge by 2029

Market Analysis and Size

Data Bridge Market Research analyses that the Global Cancer Biomarkers Market is expected to undergo a CAGR of 13.11% during the forecast period. This indicates that the market value, which was USD 11.66 billion in 2021, would rocket up to USD 51.14 billion by 2029. “Lung Cancer” dominates the product segment of the cancer biomarkers market owing to the fact that lung cancer has the highest prevalence rate in the world as compared to other cancer types. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

From the name itself, it is clear that cancer biomarkers are the biomolecules that are used for determining cancer in the body. The cancer biomarkers are effective in diagnosing the cancerous cells in a particular area or organ in the body. These biomolecules are analysed by collecting samples of stool, urine, tumour tissue, blood, and other bodily fluids.

Competitive Landscape and Cancer Biomarkers Market Share Analysis

The cancer biomarkers market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cancer biomarkers market.

Some of the major players operating in the cancer biomarkers market are

(US),
DiagnoCure Inc. (Canada),
Thermo Fisher Scientific Inc. (US),
Illumina, Inc. (US),
QIAGEN (Germany),
Hoffmann-La Roche Ltd (Switzerland),
Agilent Technologies, Inc. (US),
Quest Diagnostics Incorporated. (US),
Merck KGaA, (Germany),
Hologic, Inc. (US),
(US),
GlaxoSmithKline plc. (UK),
Novartis AG (Switzerland),
Bristol-Myers Squibb Company (US),
Eli Lilly and Company (US),
Pfizer, Inc. (US),
Genomic Health, Inc. (US),
bioMérieux SA (France),
Astellas Pharma Inc. (Japan) and
Myriad Genetics, Inc. (US)

among others.

COVID-19 Impact on Cancer Biomarkers Market

COVID-19 has significantly and negatively impacted the market. The funding for research and development activities was significantly reduced and cut down. Supply chain disruptions demoted the market demand and supply. Shifting focus towards the essential healthcare procedures during this phase put a halt on unnecessary operations. There was a huge postponement on the non-essential medical procedures. All of this proved to be a bane for the market during pandemic.

Recent Development

In March 2021, Roche received approval from US FDA for VENTANA ALK (D5F3) CDx Assay.
In July 2020, Thermo Fisher Scientific signed a companion diagnostic (CDx) agreement with Vhugai Pharmaceutical Co., Ltd to increase the use of Oncomine Dx Target Test in Japan.

Cancer Biomarkers Market Regional Analysis/Insights

The cancer biomarkers market is analysed and market size insights and trends are provided by country, type, cancer type, technology, applications and end user as referenced above.

The countries covered in the cancer biomarkers market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the cancer biomarkers market because of the strong base of healthcare facilities, rising investment from key players in the growth of the advanced devices, growing number of processes pertaining to drug development, detection of specific tumours, monitoring biological response to cancer therapy and rising number of research activities in this region.

Access Full Report:-

https://www.databridgemarketresearch.com/reports/global-cancer-biomarkers-market

Global Cancer Biomarkers Market report is a superior and comprehensive market research report which endows professionals with a lot of aspects about the market and the industry. This market research report provides a profound overview of product specification, technology, product type and production analysis considering major factors such as revenue, cost, and gross margin. Businesses can accomplish an unmatched insights and expertise of the best market opportunities into their relevant markets with the help of this market research report. An outstanding Global Cancer Biomarkers Market report is structured with the meticulous efforts of innovative, enthusiastic, knowledgeable, and experienced team of analysts, researchers, industry experts, and forecasters.

Request Access for Sample Report:-

https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cancer-biomarkers-market

Major TOC of the Report

1 INTRODUCTION

2 MARKET SEGMENTATION

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW

6 IMPACTS OF COVID-19 ON THE CANCER BIOMARKERS MARKET

7 CANCER BIOMARKERS MARKET, BY INDUSTRY TYPE

Get TOC of the Report:-

https://www.databridgemarketresearch.com/toc/?dbmr=global-cancer-biomarkers-market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best Market opportunities and foster efficient information for your business to thrive in the Market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: Sopan.gedam@databridgeMarketresearch.com

Browse Related Reports@